India has banned 47 more Chinese apps - saying they are clones of earlier outlawed products - and there are expectations that the crackdown could extend even further.
A full list has yet to be released, so it is unclear how many venture capital-backed companies were involved. However, numerous Indian competitors - including those with financial sponsors - are likely...
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.